H3D Partners with Yemaachi to Utilise African Genetic Diversity to Develop New Tools for Improving Treatment Outcomes for the African Patient Populations

Yemaachi Biotech has formed a strategic partnership with the Holistic Drug Discovery and Development (H3D) Centre at the University of Cape Town (UCT), to gain a better understanding of the pharmacogenomics of African populations and the genetic landscape of cancer among African populations, which will inform Yemaachi’s precision medicine projects. Additionally, the partnership will benefit from H3D’s expertise in drug metabolism assays that will aid in identifying genetic variations associated with liver cancer among Africans.

Because of the limited representation of Africans in trials worldwide (2% of clinical trial participants are people of African descent), very little is known about how drugs behave among African populations.

We at Yemaachi are very excited about this opportunity to partner with H3D. Not only is the project one of great importance to healthcare in Africa, but such partnerships are crucial to the development of scientific capacity on the continent – Africans working together to solve African problems

– Dr. Yaw Bediako, Yemaachi CEO

Read the official press release here.

Image credit: www.h3d.uct.ac.za